Literature DB >> 7686887

Thrombin increases the metastatic potential of tumor cells.

M Z Wojtukiewicz1, D G Tang, J J Ciarelli, K K Nelson, D A Walz, C A Diglio, E F Mammen, K V Honn.   

Abstract

Initial arrest of tumor cells in the microvasculature and their attachment to the endothelium and subendothelial matrix (SEM) are essential prerequisites for metastasis to occur. Factors mediating these interactions are viewed as important determinants of the tumor-cell metastatic phenotype. In this work we have studied the effects of thrombin, its analogs and its precursors on the adhesive properties and metastatic potential of tumor cells. We show that alpha-thrombin, the native form of the key coagulation enzyme, is capable of enhancing tumor-cell adhesion to both the endothelium and SEM components represented by fibronectin. Subclotting, physiological concentrations of alpha-thrombin produced a 2- to 5-fold increase in tumor-cell adhesion. A bell-shaped dose-response curve was observed, with maximal effect at 0.1 U/ml. Maximum effect occurred when cells were exposed to the agonist for 15 min and exposure for up to 4 hr resulted in enhanced tumor-cell adhesion. Prolonged incubation with thrombin resulted in a decline in the thrombin-enhanced adhesion which reached unstimulated control levels by 24 hr. Thrombin precursors and active-site-inhibited thrombin analogs only had minimal adhesion-enhancing activity; nitro- and exosite-alpha-thrombin, which retain a functional active site, mimicked, although to a lesser degree, the action of alpha-thrombin. Tumor-cell incubation with thrombin resulted in an upregulated cell-surface expression of the alpha11b beta 3 integrin, a receptor mediating interactions between tumor cells and endothelial cells, and between tumor cells and SEM. Antibodies against alpha 11b beta 3 integrin effectively inhibited thrombin-enhanced tumor-cell adhesion. Thrombin effects on tumor cells involved the PKC signal transduction pathway as thrombin-enhanced adhesion was inhibited by pre-incubation with PKC inhibitors and a transient PKC translocation from cytosol to membrane was observed following thrombin challenge. In vivo, thrombin-treated tumor cells demonstrated a 2-fold increase in their lung-colonizing ability. In contrast to the adhesion results, the metastasis-enhancing effects of alpha-thrombin were mimicked by a thrombin precursor (prothrombin) and thrombin analogs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686887     DOI: 10.1002/ijc.2910540514

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

Review 1.  The hemostatic system and angiogenesis in malignancy.

Authors:  M Z Wojtukiewicz; E Sierko; P Klement; J Rak
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

Review 2.  Treatment of cancer with anticoagulants: rationale in the treatment of melanoma.

Authors:  D L Ornstein; L R Zacharski
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

3.  Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues.

Authors:  M R D'Andrea; C K Derian; R J Santulli; P Andrade-Gordon
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

4.  Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells.

Authors:  Dalila Darmoul; Valérie Gratio; Hélène Devaud; Thérèse Lehy; Marc Laburthe
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

5.  Expression of protease-activated receptors and tissue factor in human liver.

Authors:  Anne Rullier; Nathalie Senant; Walter Kisiel; Paulette Bioulac-Sage; Charles Balabaud; Brigitte Le Bail; Jean Rosenbaum
Journal:  Virchows Arch       Date:  2005-09-29       Impact factor: 4.064

6.  Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation.

Authors:  T Ogiichi; Y Hirashima; S Nakamura; S Endo; M Kurimoto; A Takaku
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

7.  Protein arginine deiminase 4: a target for an epigenetic cancer therapy.

Authors:  Jessica L Slack; Corey P Causey; Paul R Thompson
Journal:  Cell Mol Life Sci       Date:  2010-08-13       Impact factor: 9.261

8.  Protease-activated receptors in cancer: A systematic review.

Authors:  Na Han; Ketao Jin; Kuifeng He; Jiang Cao; Lisong Teng
Journal:  Oncol Lett       Date:  2011-04-08       Impact factor: 2.967

9.  Blood peptidome-degradome profile of breast cancer.

Authors:  Yufeng Shen; Nikola Tolić; Tao Liu; Rui Zhao; Brianne O Petritis; Marina A Gritsenko; David G Camp; Ronald J Moore; Samuel O Purvine; Francisco J Esteva; Richard D Smith
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

10.  Distinct PAR/IQGAP expression patterns during murine development: implications for thrombin-associated cytoskeletal reorganization.

Authors:  Lisa D Cupit; Valentina A Schmidt; Frederick Miller; Wadie F Bahou
Journal:  Mamm Genome       Date:  2004-08       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.